These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34974392)

  • 1. Triple-combination therapy assisted with ultrasound-active gold nanoparticles and ultrasound therapy against 3D cisplatin-resistant ovarian cancer model.
    Kip B; Tunc CU; Aydin O
    Ultrason Sonochem; 2022 Jan; 82():105903. PubMed ID: 34974392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcome of Cisplatin Resistance in Ovarian Cancer by Combination of Low-intensity Ultrasound and Cisplatin.
    Kip B; Aydin O
    Curr Drug Deliv; 2023; 20(9):1380-1390. PubMed ID: 35761504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
    Yu T; Yang Y; Zhang J; He H; Ren X
    Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer.
    Bortot B; Mongiat M; Valencic E; Dal Monego S; Licastro D; Crosera M; Adami G; Rampazzo E; Ricci G; Romano F; Severini GM; Biffi S
    Int J Nanomedicine; 2020; 15():4793-4810. PubMed ID: 32764921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
    Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.
    Mueller T; Pfankuchen DB; Wantoch von Rekowski K; Schlesinger M; Reipsch F; Bendas G
    Molecules; 2017 May; 22(5):. PubMed ID: 28467373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of gold-nanocluster-mediated chemotherapeutic efficiency of cisplatin in lung cancer.
    Jiang M; Lin Y; Fang X; Liu M; Ma L; Liu J; Chen M; Yang Y; Wang C
    J Mater Chem B; 2021 Jun; 9(24):4895-4905. PubMed ID: 34095942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
    Huang L; Zhao L; Zhang J; He F; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; He TC; Tang L
    Aging (Albany NY); 2021 Jul; 13(13):17407-17427. PubMed ID: 34232919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles.
    Xiong X; Arvizo RR; Saha S; Robertson DJ; McMeekin S; Bhattacharya R; Mukherjee P
    Oncotarget; 2014 Aug; 5(15):6453-65. PubMed ID: 25071019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
    Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
    Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells.
    Pfankuchen DB; Stölting DP; Schlesinger M; Royer HD; Bendas G
    Biochem Pharmacol; 2015 Sep; 97(2):147-57. PubMed ID: 26239805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
    Bratasz A; Selvendiran K; Wasowicz T; Bobko A; Khramtsov VV; Ignarro LJ; Kuppusamy P
    J Transl Med; 2008 Feb; 6():9. PubMed ID: 18302761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
    Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L
    Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyphenols bearing cinnamaldehyde scaffold showing cell growth inhibitory effects on the cisplatin-resistant A2780/Cis ovarian cancer cells.
    Shin SY; Jung H; Ahn S; Hwang D; Yoon H; Hyun J; Yong Y; Cho HJ; Koh D; Lee YH; Lim Y
    Bioorg Med Chem; 2014 Mar; 22(6):1809-20. PubMed ID: 24565968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.
    El-Senduny FF; Badria FA; El-Waseef AM; Chauhan SC; Halaweish F
    Tumour Biol; 2016 Jan; 37(1):685-98. PubMed ID: 26242260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine Analogues as Opposite Modulators of the Cisplatin Resistance of Ovarian Cancer Cells.
    Bednarska-Szczepaniak K; Krzyżanowski D; Klink M; Nowak M
    Anticancer Agents Med Chem; 2019; 19(4):473-486. PubMed ID: 30657045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of cisplatin plus natural killer cells overcomes immunoresistance of cisplatin resistant ovarian cancer.
    Choi SH; Jung D; Kim KY; An HJ; Park KS
    Biochem Biophys Res Commun; 2021 Jul; 563():40-46. PubMed ID: 34058473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
    Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
    Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.